Chiasma to Participate in AACE and ECE 2016 Conferences

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Chiasma to Participate in AACE and ECE 2016 Conferences

Publishes New Data Regarding Time-Weighted Average Response Rate  from Initial Phase 3 Trial

Presents New Injectable Somatostatin Analog Patient Reported Outcome Data

Highlights Recently Initiated MPOWERED Trial

WALTHAM, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA ), a biopharmaceutical company developing an investigational new drug, Mycapssa™ (octreotide) capsules, for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today announced its participation at two upcoming medical conferences, which will include poster presentations containing patient-reported outcomes survey data, the design of a recently initiated trial and new clinical data.

2016 American Association of Clinical Endocrinologists (AACE) Annual Scientific and Clinical Congress (May 25-29 in Orlando, Florida)

Title:                A Study to Develop a Novel Patient-Reported Outcomes (PRO) Instrument to Assess Satisfaction with Acromegaly Treatment: The Acro-TSQ (Abstract #1304)

Lead author:     Maria Fleseriu, MD, FACE, professor and director of NW Pituitary Center, Oregon Health & Science University, Portland, USA

Date:               Saturday, May 28, 2016

Title:               MPOWERED™: Study Design of a Phase 3 Head-to-Head Trial Evaluating Oral Octreotide Capsules Versus Injectable Somatostatin Analogs in Patients with Acromegaly (Abstract #938)

Lead author:    Maria Fleseriu, MD, FACE, professor and director of NW Pituitary Center, Oregon Health & Science University, Portland, USA

Date:               Friday, May 27, 2016

European Society of Endocrinology’s ECE 2016 (May 28-31 in Munich, Germany)

Title:                Longitudinal Assessment of Response to Treatment with Oral Octreotide Capsules in Patients with Acromegaly: Post-hoc Analysis of a Phase 3 Trial

Lead author:     Maria Fleseriu, MD, FACE, professor and director of NW Pituitary Center, Oregon Health & Science University, Portland, USA

Date:               Monday, May 30, 2016

About Mycapssa

Mycapssa is the conditional trade name of octreotide capsules, an investigational new oral drug in development for the maintenance therapy of adult patients with acromegaly.  If approved, Mycapssa may be the first oral somatostatin analog approved for acromegaly.  Mycapssa has been granted orphan designation in the United States and the European Union for the potential treatment of acromegaly.  Chiasma received a Complete Response Letter from the U.S. Food and Drug Administration on April 15, 2016 regarding its New Drug Application for Mycapssa.  Mycapssa has not been approved for use in any jurisdiction.  

About Acromegaly

Acromegaly typically develops when a benign tumor of the pituitary gland produces too much growth hormone (GH), ultimately leading to significant health problems and early death if untreated.  There are an estimated 69,000 individuals with acromegaly worldwide.  In 13 studies of acromegaly prevalence since 1980, an average of approximately 75 cases per million was determined, suggesting roughly 24,000 individuals with acromegaly in the United States, of which an estimated 8,000 are treated chronically with somatostatin analog injections.  Because symptoms often develop slowly, diagnosis may be delayed by years or decades, making it difficult to determine the total number of people with the disease.

Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision and enlargement of the hands, feet, tongue and internal organs.  Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders and cardiac and cerebrovascular disease.

Current treatment options include surgery to remove the pituitary tumor, radiation therapy to destroy any lingering tumor cells, and/or medical treatment in cases where these approaches are not possible or fully effective.  Today's medical treatments include dopamine agonists, GH antagonists, and injectable somatostatin analogs, which are the current standard of care.

About Chiasma

Chiasma is dedicated to improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases.  Employing its Transient Permeability Enhancer (TPE ® ) technology platform, Chiasma seeks to develop oral medications that are currently only available as injections.  The company is conducting an international Phase 3 clinical trial of octreotide capsules (conditionally trade-named “Mycapssa”) for the maintenance treatment of adult acromegaly patients to support a potential submission of a Marketing Authorization Application to the European Medicines Agency.  Chiasma is headquartered in the United States with a wholly owned subsidiary in Israel.  Mycapssa and TPE are trademarks of Chiasma. 

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including , but not limited to, statements regarding the posters planned for AACE and ECE 2016.  Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the regulatory review process generally; risks associated with participating in an End of Review meeting with the FDA; risks associated with Chiasma’s Phase 3 clinical trial to support regulatory approval of Mycapssa in the E.U.; risks that prior clinical data may not be indicative of future clinical results; risks associated with obtaining, maintaining and protecting intellectual property; and the risk that octreotide capsules, if approved, will not be successfully commercialized.  For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Chiasma’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed with the Securities and Exchange Commission on May 12, 2016.  All information in this press release is as of the date of the release, and Chiasma undertakes no duty to update this information unless required by law.

Contacts: Media: Cammy Duong MacDougall Biomedical Communications (781) 591-3443 cduong@macbiocom.com Investors: Jason Fredette Chiasma, Inc. (617) 928-5306 Jason.Fredette@ChiasmaPharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 76

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 110

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 43

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Dental Exams Are Routine Until They Catch Something Early

Updated Category News Views 60

A mouth can look perfectly fine right up until it does not. That is the unglamorous value in the dental exam and X-rays visit described by Dr. Eric Runyon of Smiles Unlimited in Belton, Missouri: it is a structured look for trouble before pain, swelling, or a cracked tooth forces the issue. Nobody throws a parade for preventive care, but waiting for symptoms has a habit...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
es